Nomogram for the prediction of valproic acid induced platelet decline: a nested case-control study

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Medicine

Background:

• Valproic acid is frequently used for seizure prevention in neurosurgical patients.
• Platelet decline (thrombocytopenia) is a known complication of valproic acid therapy.
• Risk factors for valproic acid-induced thrombocytopenia and the impact of concomitant medications like levetiracetam are not well understood.

Purpose of the Study:

• To identify risk factors for valproic acid-induced platelet decline in neurosurgical patients.
• To develop and validate a predictive model for valproic acid-associated thrombocytopenia.
• To assess the role of levetiracetam in combination therapy with valproic acid regarding platelet count.

Main Methods:

• Retrospective nested case-control study involving 356 neurosurgical patients.
• Multivariate logistic regression analysis to identify independent risk and protective factors.
• Development and validation of a predictive nomogram using area under the curve (AUC) and calibration plots.

Main Results:

• Advanced age (OR: 1.05) and combination therapy with valproic acid and levetiracetam (OR: 3.03) were identified as independent risk factors for platelet decline.
• A trough valproic acid concentration below 100 μg/mL (OR: 0.41) was an independent protective factor.
• The predictive model demonstrated robust performance with AUC values of 0.85 (training) and 0.81 (validation).

Conclusions:

• A predictive model incorporating age, valproic acid-levetiracetam combination, and valproic acid trough concentration can effectively assess the risk of platelet decline.
• This model aids in managing valproic acid therapy in neurosurgical patients.
• Identifying patients at high risk for thrombocytopenia allows for proactive monitoring and potential intervention.